Trial Profile
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 24 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Etrumadenant (Primary) ; Hyaluronidase (Primary) ; Motixafortide (Primary) ; Selicrelumab (Primary) ; Simlukafusp alfa (Primary) ; Tiragolumab (Primary) ; Tocilizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms Morpheus-Pancreatic Cancer; MORPHEUS-PDAC
- Sponsors Roche
- 21 Feb 2024 According to Arcus Biosciences media release, data from this study expected to be presented in the first half of 2024.
- 22 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 20 Sep 2023 This trial has been completed in Germany, according to the European Clinical Trials Database record.